Upon viral infection, cells undergo apoptosis as a defense against viral replication. Viruses, in turn, have evolved elaborate mechanisms to subvert apoptotic processes. Here, we report that a novel viral mitochondrial anti-apoptotic protein (vMAP) of murine c-herpesvirus 68 (cHV-68) interacts with Bcl-2 and voltage-dependent anion channel 1 (VDAC1) in a genetically separable manner. The N-terminal region of vMAP interacted with Bcl-2, and this interaction markedly increased not only Bcl-2 recruitment to mitochondria but also its avidity for BH3-only pro-apoptotic proteins, thereby suppressing Bax mitochondrial translocation and activation. In addition, the central and C-terminal hydrophobic regions of vMAP interacted with VDAC1. Consequently, these interactions resulted in the effective inhibition of cytochrome c release, leading to the comprehensive inhibition of mitochondrion-mediated apoptosis. Finally, vMAP gene was required for efficient cHV-68 lytic replication in normal cells, but not in mitochondrial apoptosis-deficient cells. These results demonstrate that cHV-68 vMAP independently targets two important regulators of mitochondrial apoptosis-mediated intracellular innate immunity, allowing efficient viral lytic replication. 
Introduction
Apoptosis, or programmed cell death, has a key role in a variety of eukaryotic biological processes such as development and immune responses. Whether initiated by receptor ligation at the cell surface or through signal transduction from intracellular organelles, both caspase-dependent andindependent apoptotic pathways degrade cellular components, leading to the complete dismantling of targeted cells. Particularly, mitochondria serve as gatekeepers for the lifeor-death decision, conveying apoptotic signals by releasing death-promoting factors (e.g., cytochrome c, apoptosisinducing factor, and DIABLO/Smac from the intermembrane space [1] [2] [3] [4] ).
Recent studies have largely elucidated the complex mechanism that eukaryotes have evolved to regulate the permeability of the mitochondrial outer membrane during apoptosis, particularly with regard to Bcl-2 homology (BH) family proteins [5] [6] [7] . Bcl-2 family members are classified as either anti-apoptotic (e.g., Bcl-2, Bcl-x L , Bcl-w, and A1) or pro-apoptotic, the latter of which can be further divided into the multi-BH domain and BH3-only subgroups. Similar to anti-apoptotic proteins, the multi-BH domain members, such as Bax and Bak, adopt a globular fold consisting of up to nine a-helices that form an extended hydrophobic cleft on the surface [8] . This cleft serves as an authentic BH3-binding site that mediates their translocation and oligomerization within the mitochondrial outer membrane and, ultimately, mitochondrial permeabilization [6, 9] .
Additional regulation of the mitochondrion-dependent apoptosis is mediated by the permeability transition pore (PTP), a complex composed of the voltage-dependent anion channel (VDAC) and adenine nucleotide translocator (ANT). VDAC is located in the mitochondrial outer membrane, and its transmembrane can form a barrel with a pore size consistent with the estimated open-channel diameter to allow the escape of cytochrome c. A direct interaction between Bcl-2 family members and VDAC may control cytochrome c permeation across membranes [7, 10] . Alternatively, VDAC-mediated closure of the PTP supercomplex may prevent ATP/ADP exchange across the membrane, which ultimately results in outer membrane permeabilization and subsequent release of pro-apoptotic factors from the intermembrane space; this, in turn, triggers apoptosis in the cytoplasm or nucleus [10] . Although current studies favor the latter model, these hypotheses may not be mutually exclusive in defining the nature of the PTP complex. Apoptosis is part of host innate immunity that eliminates the propagation of intracellular pathogens such as viruses. As a countermeasure, viruses have evolved to encode numerous open reading frames (ORFs) to circumvent cellular apoptotic pathways. Herpesviruses, particularly c-herpesviruses, including human Epstein-Barr virus, Kaposi sarcoma-associated herpesvirus, and murine c-herpesvirus 68 (cHV-68), provide unique models for dissecting the molecular mechanisms of apoptotic regulation. A common aspect of these c-herpesviruses is that they encode viral homologs of Bcl-2, designated vBcl-2, and these vBcl-2 genes effectively prevent cells from undergoing apoptosis upon various stress responses [11, 12] . vBcl-2 has been speculated to serve a vital role in the virus lifecycle by inhibiting the premature apoptotic death of host cells during acute replication, allowing completion of viral replication cycle and favoring the spread of progeny virus. However, the previous studies have found that cHV-68 vBcl-2 has no role during acute infection but its activity is critical specifically to latent infection [13] [14] [15] . Thus, to identify viral protein that evades host apoptosis-mediated innate immunity during acute infection, we searched for mitochondrial proteins within the cHV-68 genome. We report that viral mitochondrial anti-apoptosis protein (vMAP) specifically interacts with cellular Bcl-2/Bcl-x L and VDAC and that these interactions effectively dampen host apoptotic processes, which ultimately contributes to efficient lytic replication in culture.
Results

The cHV-68 vMAP Gene Encodes a Mitochondrial AntiApoptotic Protein
To test the role of the mitochondrion-dependent apoptosis in cHV-68 replication, wild-type (wt) and Bax À/À Bak À/À double knockout (DKO) murine embryonic fibroblasts (MEFs) were infected with a GFP-containing cHV-68 (cHV-68DK3-GFP). DKO MEFs supported cHV-68DK3-GFP replication with accelerated kinetics as compared with wt MEFs: the virus titer in DKO MEFs was 50-100 times higher than that in wt MEFs ( Figure S1A and S1B). Furthermore, as previously shown [16] , DKO MEFs displayed markedly reduced cell death upon cHV-68 replication than did wt MEF ( Figure S1C and S1D). These results indicate that mitochondrion-mediated apoptosis plays a negative role in cHV-68 lytic replication, suggesting that cHV-68 needs to deregulate this pathway to maximize its propagation. To search for the potential mitochondrial protein(s) encoded by cHV-68, we employed two computer programs, MITOProt (http://mips.gsf.de/ cgi-bin/proj/medgen/mitofilter) and PSORT (http://psort. nibb.ac.jp/), which assess the likelihood of each candidate viral gene product to be targeted to the mitochondrion. This survey identified an M8 gene product [17] that we have named vMAP. vMAP is present in the second exon of ORF57 and shares the identical nucleotide sequence with ORF57 ( Figure 1A ). However, vMAP has a þ1 shift in reference to ORF57 frame, thus encoding a polypeptide of distinct amino acid sequence from ORF57. vMAP contains 157 amino acids, with a predicted mitochondrial targeting sequence (MTS) at its N-terminus and a putative transmembrane domain at its C-terminus ( Figure 1B ). vMAP protein was readily detected during cHV-68 lytic replication with an apparent molecular weight of 16 kDa ( Figure 2A , left panel). However, we failed to detect vMAP protein in cHV-68 latently infected S11 cells under the same conditions (unpublished data). When vMAP expression vector was transfected into NIH3T3 cells, however, vMAP migrated as 7-, 14-, and 16-kDa species ( Figure  2A , right panel). Mutational analyses indicated that the 7-and 14-kDa proteins were derived from translational initiation at the third (Met 70 ) and second (Met 21 ) internal initiation codon, respectively (unpublished data). Intracellular fractionation demonstrated that vMAP was present exclusively in the mitochondrion-enriched heavy membrane (HM) fraction ( Figure 2A , right panel). The position and integrity of the fraction was confirmed by the presence of the mitochondrial resident protein COX4. Confocal immunofluorescence microscopy also showed that vMAP was present in the cytoplasm extensively colocalized with MitoTracker, a dye that specifically labels mitochondria in living cells, and with Hsp60 and cytochrome c mitochondrial resident proteins (Figures 2B, S2A, and S2C). GFP fusions containing the N-terminal region of vMAP were constructed to define the MTS of vMAP. The N-terminal 40 residues of vMAP were sufficient to target GFP to mitochondria ( Figure 2C ). Interestingly, this N-terminal sequence of vMAP is predicted to contain a-helical structure, followed by a stretch of positively charged residues that are the potential MTS motif ( Figure 1A ). In fact, deletion mutations within this motif considerably impaired the mitochondrial localization of GFP fusions containing vMAP N-terminal sequences in confocal microscopy and intracellular fractionation ( Figures 2C and S2B ). Of note, the vMAP(1-30)-GFP and vMAP(21-49)-GFP also showed the nuclear localization, which was likely contributed by GFP fusion ( Figure 2C ). These results indicate that the N-terminal 40 residues are sufficient for mitochondrial targeting activity.
To assess vMAP function in apoptosis, polyclonal NIH3T3/ puro and NIH3T3/vMAP stable cell lines were established.
Author Summary
Apoptosis is a conserved cell death program that contributes to restriction of viral replication and elimination of infected cells. Whether triggered via internal inducers such as DNA damage or via external stimuli such as engagement of the death receptor, apoptosis takes place through a cascade of regulated internal proteolytic digestion, resulting in a collapse of cellular infrastructure, mitochondrial potential, genomic fidelity, and cell membrane integrity. Indeed, apoptosis represents a predominant form of virally infected cell demise. In response, viruses have evolved numerous ways of circumventing this host-cell apoptosis. Most of the DNA viruses including murine c-herpesvirus 68 (cHV-68) are genetically equipped with anti-apoptotic ability to ensure viral replication and propagation. The authors have identified a new viral mitochondrial protein (vMAP) of cHV-68 that interacts with Bcl-2 and voltage-dependent anion channel 1 (VDAC1) in a genetically separable manner. These interactions markedly suppress Bax mitochondrial translocation and activation and inhibit cytochrome c release, leading to the comprehensive inhibition of mitochondrion-mediated apoptosis. The authors also demonstrate that vMAP gene is required for efficient cHV-68 lytic replication in normal cells, but not in mitochondrial apoptosis-deficient cells. These findings are entirely novel and significantly advance our understanding of how virus escapes host intracellular apoptosis-mediated innate immunity.
The expression of vMAP was confirmed by immunoblotting with anti-vMAP serum as shown in Figure 2D . These cells were treated with various apoptotic agents and stresses (staurosporine [ST] , TNF-a, vesicular stomatitis virus infection, and nocodazole) to induce apoptosis, stained with propidium iodide (PI), and then analyzed by flow cytometry. vMAP expression significantly reduced the accumulation of sub-G1 cells that are considered to be apoptotic ( Figure 2D and 2E). These results demonstrate that cHV-68 vMAP has robust anti-apoptotic activity toward various apoptotic agents.
vMAP Interaction with Bcl-2 Family Proteins
To investigate the molecular action of vMAP, we tested whether vMAP interacts with cellular apoptotic or antiapoptotic proteins of the Bcl-2 family. Co-immunoprecipitation analyses showed that vMAP interacted with cellular Bcl-2 in transiently vMAP-expressing 293T cells and in cHV-68-infected NIH3T3 cells ( Figures 3A and S3A ). In addition, vMAP interaction with cellular Bcl-x L was readily detected in cHV-68-infected NIH3T3 cells ( Figure 3A) . Despite the equivalent expression of three different species of vMAP in 293T cells, the 16-kDa vMAP predominantly interacted with Bcl-2, suggesting that the N-terminal sequence of vMAP is likely required for Bcl-2 interaction ( Figure S3A ). To further define the interaction between vMAP and Bcl-2 family proteins, a mammalian GST fusion protein containing vMAP (1-50) was coexpressed in 293T cells along with HA-tagged Bcl-2, Bcl-x L , Bax, Bak, Bid, or Bad. vMAP(1-50)-GST efficiently interacted with Bcl-2 and Bcl-x L but not with Bax, Bak, Bad, or Bid ( Figure 3B and unpublished data). However, vMAPD20-GST fusion lacking the N-terminal 20 amino acids completely lost its ability to bind to Bcl-2 and Bcl-x L ( Figure 3C ). Interestingly, the N-terminal sequence containing the first 20 amino acids of vMAP is predicted to adopt an amphipathic helical structure and share limited similarity with the BH3 peptide of Bad (unpublished data). However, deletion mutation analysis indicated that unlike the BH3 peptide binding that requires the BH1, BH2, and BH3 domains of Bcl-2, the vMAP binding required the Bcl-2 85-186-aa region containing the BH1 and BH3 domains only in living cells ( Figure S3B ). This was further supported by the results that Bcl-2 G 145A mutation in the BH1 domain abolished vMAP binding, whereas Bcl-2 W 188A mutation in the BH2 domain did not affect vMAP binding ( Figure 3D ). By contrast, both mutations of Bcl-2 completely abrogated its Bid-binding activity under the same conditions ( Figure S3C ). This suggests that Bcl-2 binding to vMAP is different from its binding to BH3-only proteins.
vMAP Interaction Facilitates Bcl-2 Mitochondrial Localization
Bcl-2 family members are found in the cytoplasm, the endoplasmic reticulum, and the nuclear membrane where they act as sensors of cellular damage or stress. Upon stress, members of Bcl-2 family proteins relocate to the mitochondrial surface where they exert their activity [6, 18, 19] . Thus, mitochondrial recruitment of Bcl-2 is considered an important step during the pro-or anti-apoptotic decision. To examine whether vMAP interaction affected Bcl-2 intracellular localization, the distribution of Bcl-2 was examined by subcellular fractionation. Whole-cell lysates were subjected to sequential centrifugation to obtain light membrane (LM) fraction containing microsomes derived from the endoplasmic reticulum or the trans Golgi network, HM fraction enriched with mitochondria, and cytosolic fraction. Densitometry quantification of immunoblotting revealed that approximately 70% and 30% of Bcl-2 was present in LM and HM of NIH3T3/puro cells, respectively, whereas 30% and 70% of Bcl-2 was present in the LM and HM of NIH3T3/ vMAP cells, respectively ( Figure 4A ). vMAPD20 mutant that failed to interact with Bcl-2 showed only a little effect on Bcl-2 localization compared with wt vMAP ( Figure 4A ). It should be noted that despite the 20-aa deletion at the N-terminus, vMAPD20 mutant was still present primarily in the mitochondrion-enriched HM, as shown in Figures 4A and S2D , suggesting that vMAP may contain at least two independent motifs for its mitochondrial localization. To further test if vMAP recruited Bcl-2 into the mitochondrion in vitro, HM factions were used for mitochondrial association assay with [
35 S]-labeled Bcl-2 translated in rabbit reticulocyte lysates. Bcl-2 mitochondrial association activity increased approximately 2-fold in the HM fractions of NIH3T3/vMAP cells compared with those of NIH3T3/puro cells ( Figure 4B ). These results collectively indicate that vMAP actively recruits Bcl-2 to mitochondria, and that this vMAP activity requires the specific interaction with Bcl-2.
vMAP Potentiates Bcl-2/Bcl-x L to Neutralize BH3-Only Molecules
The ability to associate with BH3-only molecules correlates with the anti-apoptotic activity of Bcl-2 and Bcl-x L [20, 21] . Because vMAP facilitated the mitochondrial recruitment of Bcl-2, we tested whether vMAP expression affected the ability of Bcl-2 and Bcl-x L to associate with BH3-only molecules. NIH3T3/puro and NIH3T3/vMAP cells were transfected with Flag-tagged Bcl-2 and HA-tagged Bad or Bid. At 36 h posttransfection, cell lysates were used for immunoprecipitation with anti-HA, followed by immunoblotting with anti-Flag. Surprisingly, the interaction of Bcl-2 with Bad or Bid was considerably higher in NIH3T3/vMAP cells than in NIH3T3/ puro cells ( Figure 5A and 5B). vMAP expression also had a similar effect on the Bcl-x L -Bad interaction ( Figure 5C ). In contrast, vMAP expression affected neither Bcl-2/Bcl-x L interaction with Bax/Bak, nor Bcl-x L dimerization under the same conditions ( Figure S3D , S3E, and unpublished data). vMAPD20, which failed to interact with Bcl-2 and Bcl-x L but still localized at mitochondria, had no effect on their interactions with Bid or Bad ( Figure 5A and 5C, lane 4).
To further demonstrate the effect of vMAP on Bcl-2 interaction with BH3-only molecules in living cells, a flow cytometry-based fluorescence resonance energy transfer (FRET) assay was used to quantify the interaction between Bcl-2 and Bid. NIH3T3/puro, NIH3T3/vMAP, and NIH3T3/ vMAPD20 cells were transfected with EYFP-Bcl-2 and ECFPBid expression vectors. At 36 h post-transfection, these cells were subjected to a FRET assay. The Bcl-2-Bid interaction increased approximately 2-to 3-fold in NIH3T3/vMAP cells as compared with NIH3T3/puro cells, whereas no significant difference was detected between NIH3T3/puro and NIH3T3/ vMAPD20 cells ( Figure 5D ). Furthermore, consistent with immunoprecipitation results ( Figure S3D and S3E), vMAP did not significantly alter the Bcl-2-Bax interaction in the FRET assay ( Figure S3F ). These results demonstrate that vMAP specifically facilitates the interactions of Bcl-2/Bcl-x L with Bid/Bad.
vMAP Inhibits the Activation and Mitochondrial Translocation of Bax BH3-only pro-apoptotic proteins transduce death signals from the cell surface or intracellular apoptotic pathways by inducing a conformational change in Bax. Subsequently, Bax translocates to mitochondria and oligomerizes within the outer membrane, which ultimately leads to membrane permeabilization and release of pro-apoptotic factors from the intermembrane space [5, 22] . To test if vMAP expression affected Bax activation, mouse monoclonal antibody 6A7 that specifically recognizes an epitope in the pro-apoptotic Bax conformer was used to assess the level of Bax activation [23] . NIH3T3/puro and NIH3T3/vMAP cells were treated with ST (1 lM) for 4 h, lysed with 1% CHAPS buffer, and subjected to immunoprecipitation with the 6A7 monoclonal antibody or the P-19 rabbit polyclonal antibody that reacts with total Bax. NIH3T3/vMAP cells reproducibly showed lower levels of the pro-apoptotic Bax conformer ( Figure 6A ). This difference was not due to a reduced level of Bax expression, as immunoprecipitation and immunoblotting with the P-19 antibody showed the equivalent amounts of Bax in both cells ( Figure 6A ). Confocal immunofluorescence microscopy also showed that vMAP expression substantially suppressed the ST-induced Bax activation in HeLa cells ( Figure 6B ). In contrast, vMAPD20, which failed to interact with Bcl-2/Bcl-x L , did not affect Bax activation ( Figure 6B ). Quantification of 6A7 Bax antibody-positive cells showed that over 70% of vMAPD20-expressing cells were positive to the 6A7 Bax conformer antibody at 4 h after ST treatment, whereas only 25% of vMAP-expressing cells were positive ( Figure 6B ). Subcellular fractionation was further used to examine the mitochondrial translocation of Bax. NIH3T3/puro, NIH3T3/ vMAP, and NIH3T3/vMAPD20 cells were treated with ST (1 lM) for 4 h, and equivalent amounts of HM were used for immunoblotting. Upon ST treatment, endogenous Bax efficiently translocated into mitochondria in NIH3T3/puro and NIH3T3/vMAPD20 cells, whereas a significant reduction of Bax mitochondrial translocation was detected in NIH3T3/ vMAP cells ( Figure 6C ). Equivalent amounts of Bax expression were detected in all three cells ( Figure 6C ). Collectively, these data indicate that vMAP expression significantly suppresses Bax activation as well as its mitochondrial translocation.
The Central and C-Terminal Hydrophobic Regions of vMAP Interact with VDAC1
While the N-terminal 50 residues of vMAP were sufficient for interacting with Bcl-2 and this interaction exhibited a pleiotropic effect on Bcl-2 family proteins, the loss of Bcl-2 interaction did not completely impede vMAP-mediated antiapoptosis (see below). This suggests that vMAP might have additional cellular targets to achieve anti-apoptotic activity.
To test this idea, we used the yeast two-hybrid screen with vMAP 50-157-aa region as bait to search for vMAP-interacting cellular protein(s). This study identified cellular VDAC1 as a vMAP-interacting protein. An in vitro GST pull-down experiment showed that vMAP specifically bound to cellular VDAC1 ( Figure 7A , right panel, lane 1). vMAP contains two leucine-rich (LLxL, LIxL, and LxLV) hydrophobic regions consisting of residues 50-66 and 135-157 ( Figure 7A , dark grey box). To test whether these hydrophobic regions mediated the interaction with VDAC1, bacterial GST-vMAP(50-157), GST-vMAP(66-135), GSTvMAP(50-135), and GST-vMAP(66-157) fusion proteins were used for in vitro GST pull-down assays, followed by immunoblotting with antibody to VDAC1. GST fusions containing either hydrophobic region 50-66 or 135-157 effectively interacted with endogenous VDAC1. GST alone or GST-vMAP(66-135) did not interact with VDAC1 under the same conditions ( Figure 7A) . Furthermore, the vMAP L/A mutant carrying the replacement of the leucine and isoleucine residues in both hydrophobic regions with alanines no longer interacted with VDAC1 ( Figure 7B ). NIH3T3 cells stably expressing wt vMAP, vMAPD20, or vMAP L/A at equivalent levels ( Figure S2E ) were tested for vMAP and VDAC1 interaction. Both vMAP wt and vMAPD20 efficiently interacted with VDAC1, whereas vMAP L/A mutant did not interact with VDAC1, indicating that the leucine-rich motifs within the hydrophobic regions of vMAP are required for its interaction with VDAC1 ( Figure 7C ). Finally, vMAP interaction with VDAC1 was readily detected in cHV-68-infected NIH3T3 ( Figure 7D ). Cellular VDAC1 is located at the mitochondrial outer membrane and has a role in the release of pro-apoptotic factors such as cytochrome c upon apoptotic stress [24] . To test whether the vMAP-VDAC1 interaction affected cytochrome c release, NIH3T3/puro and NIH3T3/vMAP cells were treated with ST for 4 h and subjected to intracellular fractionation, followed by immunoblotting with antibodies to cytochrome c and COX4. This showed the significant release of mitochondrial cytochrome c to the cytosol in NIH3T3/puro cells, whereas only minimal cytochrome c leaked from mitochondria in NIH3T3/vMAP cells ( Figure  7E ). Finally, NIH3T3/vMAP L/A cells displayed considerable release of mitochondrial cytochrome c upon ST treatment; however, the extent of release was relatively lower in NIH3T3/ vMAP L/A cells than in NIH3T3/puro cells ( Figure 7E ). Taken together, these results indicate that vMAP interacts with mitochondrial outer membrane VDAC1 and that this interaction robustly inhibits cytochrome c release. Effect of Bcl-2 and VDAC1 on vMAP-Mediated AntiApoptotic Activity
The biological significance of the vMAP interactions with Bcl-2/Bcl-x L and VDAC1 in anti-apoptosis was tested by examining the effect of wt vMAP and its mutants (D20, L/A, D20&L/A) on Bcl-2-Bid interaction, Bax translocation and activation, cytochrome c release, and apoptosis (PI staining). While vMAPD20 had no effect on the Bcl-2-Bid interaction and Bax translocation/activation, the vMAP L/A mutant potentiated the Bcl-2-Bid interaction and inhibited Bax translocation/activation as efficiently as wt vMAP ( Figure 8A-8C) . Functionally, vMAP activity to inhibit cytochrome c release was detectably impaired by both mutations (D20 and L/A), consistent with the finding that Bax permeabilizes the mitochondrial outer membrane to release cytochrome c ( Figure 8D ). These data indicate that vMAP targets two mitochondrial apoptosis checkpoint proteins, Bcl-2/Bcl-x L and VDAC1, in a genetically separable manner.
To further investigate the significance of vMAP interactions with Bcl-2 and VDAC1 in the inhibition of apoptosis, NIH3T3 cells expressing wt vMAP or its mutants were treated with ST for 16 h. ST treatment induced extensive apoptosis in NIH3T3/puro cells, whereas wt vMAP efficiently blocked STinduced apoptosis ( Figure 8E ). In contrast, L/A and D20 mutations significantly impaired the anti-apoptotic activity of vMAP under the same conditions ( Figure 8E) . Finally, the D20&L/A double mutations completely abrogated the ability of vMAP to inhibit ST-induced apoptosis ( Figure 8E ). These results indicate that the Bcl-2 interaction displays a more pronounced role in the vMAP-mediated anti-apoptosis than the VDAC1 interaction, and both interactions lead to the comprehensive inhibition of the mitochondrion-mediated apoptosis.
vMAP Is Required for Efficient Lytic Replication of cHV-68 in Normal Fibroblasts but Not in Bax/Bak-Deficient Fibroblasts
To investigate the effect of vMAP on cHV-68 lytic replication, the bacterial artificial chromosome system was used to generate recombinant cHV-68 DvMAP that contained the removal of first Met 1 and second Met 21 residues and the insertion of a stop codon without affecting ORF57 coding sequences (for details of nucleotide changes, please see Materials and Methods). cHV-68 DvMAP Kan R Bac was initially constructed and subsequently used to generate cHV-68 DvMAP and the revertant virus, called cHV-68 Rev, which contained wt vMAP sequence ( Figure S4A ). vMAP protein was readily detected in wt and revertant cHV-68-infected cells but not in cHV-68 DvMAP-infected cells ( Figure  S4B ). To test if vMAP played a role in virus lytic replication, wt cHV-68, cHV-68 DvMAP, and cHV-68 Rev were used to infect NIH3T3, wt MEF, and Bax lower in NIH3T3 and wt MEF cells throughout replication cycle than they were in wt cHV-68 and cHV-68 Rev ( Figure  9A and 9B). However, this reduced replication capacity of cHV-68 DvMAP was considerably diminished in Bax
DKO MEFs: cHV-68 DvMAP replicated at similar kinetic and slightly reduced peak titer compared to wt cHV-68 ( Figure  9B ). To further define the role of vMAP in mitochondrial cell death during viral replication, mouse fibroblast cells were infected with wt cHV-68 or cHV-68 DvMAP, and Bax activation was then examined by immunoprecipitation and confocal microscopy with 6A7 Bax conformer antibody. After treatment with ST (1 lM, 4 h), wt cHV-68-infected cells showed the greatly reduced level of activated Bax compared to mock-infected or cHV-68 DvMAP-infected cells ( Figure 9C  and 9D ). These results demonstrate that the vMAP gene is required for efficient cHV-68 lytic replication in normal fibroblast cells, but not in mitochondrial apoptosis-deficient 
Discussion
Here, we report the identification of a novel mitochondrial anti-apoptotic vMAP of cHV-68, of which its N-terminal MTS is sufficient for the mitochondrial localization. vMAP interacts with Bcl-2 and increases Bcl-2 mitochondrial localization, leading to the neutralization of BH3-only proapoptotic molecules. Additionally, vMAP binds to the mitochondrial VDAC1 through its internal and C-terminal hydrophobic sequences, thereby inhibiting cytochrome c release upon apoptotic stresses. Taken together, these data indicate that vMAP engages cellular Bcl-2 and VDAC apoptosis checkpoint proteins to comprehensively inhibit the mitochondrion-mediated intracellular innate immunity, which allows completion of efficient viral lytic replication ( Figure 9E ).
Previous functional studies have classified BH3-only proteins as either death agonists such as Bid and Bim or survival antagonists like Bad [22, 25] . Recently, this has been formally proposed as the ''hierarchy model'', which postulates that the survival antagonist mainly promotes apoptosis by neutralizing anti-apoptotic Bcl-2 members, the death agonist induces a conformational change, oligomerization, and activation of Bax/Bak through a ''hit-and-run'' mechanism, thereby amplifying apoptotic signaling with a limited amount of cleaved Bid or dephosphorylated Bim [26] . In normal cells, the death agonist is held in check by anti-apoptotic Bcl-2 family proteins. When apoptosis is triggered, the survival antagonist binds to anti-apoptotic Bcl-2 proteins that release the death agonist, which subsequently activates Bax or Bak. This model places the survival antagonist upstream of the death agonist. Thus, BH3-only proteins display a synergistic effect in activating Bax/Bak and inducing apoptosis [22, 25] . Our data is in support of the hierarchy model regarding the action of BH3-only molecules. Conceivably, vMAP interaction may activate Bcl-2/Bcl-x L to adopt their anti-apoptotic conformation, effectively neutralizing the pro-apoptotic BH3-only molecules through a direct interaction, which ultimately blocks Bax activation. It has been shown that cellular orphan nuclear receptor Nur77 has an activity to modulate Bcl-2 conformation and convert Bcl-2 into a pro-apoptotic molecule [27] . This suggests that vMAP may resemble Nur77 by altering cellular Bcl-2/Bcl-x L conformation, but this activity transforms Bcl-2 into an anti-apoptotic conformation rather than a pro-apoptotic form. However, it should be noted that the vMAP exhibits no specificity in Bcl-2 interactions with the death agonist Bid or the survival antagonist Bad. It is possible that vMAP increases the pool of activated anti-apoptotic Bcl-2 in general, which is reflected by the elevated interaction with Bid as well as Bad. In contradiction to the hierarchy model, BH3-only molecules have recently been proposed to induce apoptosis primarily through neutralization of Bcl-2 anti-apoptotic proteins, but not through activation of Bax/Bak [28] . The reason for this seemingly discrepancy between these two models is not clear and may be derived from various different mutant proteins and functional tests that each study relied on [26, 28] . Thus, further studies are required to resolve this issue regarding BH3-only molecules. Nevertheless, our data indicate that the vMAP facilitates the interactions of Bcl-2/Bcl-x L with Bid/Bad BH3-only molecules, which neutralizes Bid/Bad pro-apoptotic activity, inhibits Bax activation, and thereby likely raises the threshold for cells to execute apoptosis. In addition to Bax/Bak activation, the PTP complex represents an additional apoptotic checkpoint within the mitochondrial membrane. Along with accessory components, the PTP complex is mainly composed of ANT and VDAC that connect the mitochondrial outer membrane with its inner membrane at contact sites. Although ANT and VDAC may not be required for mitochondrion permeabilization, accumulating data indicate that they are implicated in releasing pro-apoptotic factors from the intermembrane space [7, 24, 29, 30] . Cellular Bcl-2 family proteins and viral polypeptides differentially modulate the PTP complex through a direct interaction with ANT, VDAC, or their accessory components, and therefore regulate apoptosis [7, [31] [32] [33] . Our present study adds vMAP to the expanding family of proteins that influence the permeability transition by virtue of protein-protein interactions. The two vMAP LLxL repeats independently mediate an interaction with VDAC1 that is required to efficiently inhibit cytochrome c release, an indication of the mitochondrial permeability transition.
We have defined two functional domains within vMAP: the N-terminal Bcl-2-binding domain and the central/C-terminal VDAC1 interaction domain. It is reasonable to speculate the potential presence of a ternary complex consisting of vMAP, Bcl-2, and VDAC1. Given that Bcl-2 physically and functionally interacts with VDAC1 [7] , the introduction of vMAP to this complex may influence the Bcl-2/VDAC1 interaction if a ternary complex is present. However, we observed no detectable effect of vMAP on the interaction between Bcl-2 and VDAC1 ( Figure S5 ). On the other hand, it is also possible that vMAP independently binds to cellular Bcl-2 or VDAC1.
Consistent with this, the aforementioned two binding domains of vMAP are genetically separable in that mutations within each domain only affect its corresponding interaction, leaving the other interaction intact. Alternatively, the formation of a ternary complex may be dependent on the integrity of a lipid bilayer. Therefore, additional approaches other than traditional immunoprecipitation are required to assess vMAP interactions with Bcl-2 and VDAC1.
While both Bcl-2 and VDAC1 interactions are essential for vMAP-mediated inhibition of apoptosis, Bcl-2 binding seems to be more functionally important in vMAP-mediated inhibition of apoptosis than that of VDAC1. This is consistent with the findings that Bax and Bak are the essential players that open the mitochondrial gate to the cell death program [6, 9] . In addition, Bcl-2 family proteins are also important in regulating cytochrome c release during apoptosis. Indeed, vMAPD20 that no longer bound to Bcl-2 partially lost its activity to inhibit cytochrome c release ( Figure 8C ). While vMAP L/A mutant that no longer bound to VDAC1 significantly failed to block cytochrome c release, a detectable amount of cytochrome c was still retained in the mitochondrion in these cells ( Figure 7E ). These data support the idea that vMAP interaction with Bcl-2 also plays a role in the inhibition of cytochrome c release. Taken together, these results indicate that vMAP interactions with both Bcl-2 and VDAC1 synergistically contribute to its inhibition on the mitochondrion-mediated apoptosis.
The N-terminal MTS of vMAP entirely overlaps with its Bcl-2 binding motif. This suggests that the N-terminal deletion mutation, vMAPD20, may ablate two functions of vMAP simultaneously: Bcl-2 binding and mitochondrial targeting. However, the results of cell fractionation and confocal microscopy showed that the majority of vMAPD20 still localized to the mitochondrion (Figures 4A and S2D ). This indicates that vMAPD20 mutation ablates only the Bcl-2 binding activity without significantly affecting vMAP mitochondrial localization. This also suggests the presence of additional mitochondrial targeting sequence. Unfortunately, our GFP fusion strategy failed to identify additional linear sequence for its mitochondrial localization (unpublished data). This implies that, perhaps, a higher order of structure of vMAP may be required to function as an MTS as seen with VDAC [34] . The cleavable N-terminal MTS generally sends protein into the matrix or interior membrane of mitochondria, while the uncleavable N-terminal MTS targets protein into the outer membrane of mitochondria [35] . In fact, vMAP N-terminal MTS appeared to be not cleaved based on its molecular weight in SDS-PAGE (Figures 2A and 4A) . Additionally, a mutation at the potential mitochondrial signal peptide cleavage site of vMAP did not affect its mitochondrial localization (unpublished data). These results collectively suggest that an alternative MTS exists in addition to the Nterminal MTS.
The expression profile and function activity of cHV-68 vMAP has unique features. First, vMAP is present within the second exon of the ORF57 transcript, which encodes an immediate early gene product that is essential for viral replication, a homolog of herpes simplex virus ICP27 [17, 36] . This suggests that the vMAP gene has co-evolved with ORF57 and likely plays a critical role in cHV-68 replication. Second, the putative N-terminal amphipathic a-helical region of vMAP has both mitochondrial targeting and Bcl-2-binding activities. Of note, the vMAP contains an unidentified MTS, in addition to its N-terminal MTS, that potentially targets vMAP to the outer membrane of mitochondria. Finally, vMAP targets two mitochondrial proteins, Bcl-2 and VDAC1, to affect a comprehensive inhibition of the mitochondriondependent apoptosis. Interestingly, human cytomegalovirus (HCMV) vMIA uses a similar strategy to deregulate mitochondrion-dependent apoptosis: vMIA neutralizes and inhibits permeability transition pore activity through its direct interactions with Bax [32, 37, 38] . Intriguingly, vMIA is also encoded within the first exon of UL37 of HCMV, an immediate early gene transcript that is required for viral replication [39, 40] . However, inactivating the vMIA expression by mutagenesis did not dramatically reduce HCMV lytic replication, similar to what we reported here for vMAP deletion for cHV-68 lytic replication in tissue culture [41] . Thus, it is surprising that these viruses have undergone convergent evolution, evolving independently to encode mitochondrial proteins with similar molecular mechanisms but without discernable sequence similarity.
Materials and Methods
Cells, virus, and plaque assays. NIH3T3, NIH3T12, BHK21, COS-1, and 293T cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM Lglutamine, 100 U/ml streptomycin and penicillin. BJAB and S11 cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum, L-glutamine, and antibiotics. Fugene 6 (Roche), lipofectamine (Invitrogen), or calcium phosphate (Clontech) was used for transient expression of vMAP in COS-1, NIH3T3, and 293T cells. NIH3T3 stable cell lines were established using a standard protocol of puromycin selection at 2 lg/ml. wt MEFs or Bax cHV-68 wt and GFP viruses were amplified in NIH3T12 cells. After three rounds of freeze-thawing, supernatants of virus-infected cells were used for de novo infection of BHK21 or NIH3T12 cells. Plaque assays were performed in BHK21 cells overlaid with 1% methylcellulose as described previously [42] .
cHV-68 recombinant virus. cHV-68DK3-GFP was kindly provided by Dr. Philip Stevenson. To generate vMAP deletion recombinant virus, the bacterial artificial chromosome [43] containing the entire cHV-68 genome was used. Due to the fact that the vMAP coding sequence overlaps with ORF57, we generated cHV-68 DvMAP by changing the first and second initiation codons of vMAP to AAG and introducing two stop codons (T . A changes at nucleotide positions of 76016, 76049, 76076, and a G . A change at nucleotide position of 76079 based on Entrez accession number U97553). These changes did not affect the ORF57 coding sequence. Initially, the vMAP coding sequence was replaced with a Kan R /LacZ cassette (cHV-68 Bac DvMAP Kan R ) by allelic exchange [42] ( Figure S4A ). Since ORF57 was required for cHV-68 replication, vMAP sequences containing various mutations were amplified by PCR and electroporated into BHK21 cells together with cHV-68 Bac DvMAP Kan R DNA to allow homologous recombination. Viruses obtained from BHK21 cells, cHV-68 DvMAP or cHV-68 Rev, were plaque purified and further amplified in BHK21 cells ( Figure S4A ). Virion DNAs were used for PCR amplification to clone ORF57 and vMAP DNA fragments, followed by DNA sequence to confirm the presence of designed changes and the absence of aberrant changes. Virion DNA was also digested with BamHI or BglII to exclude the possibility of viral genomic rearrangement ( Figure S4C ). Viruses were then used to infect NIH3T3 or BHK21 cells to determine replication kinetics.
Antibody production. His-tagged vMAP (1-135) was purified from E. coli strain BL21 using Ni-conjugated agarose according to manufacturer's instructions (Qiagen). Urea was removed using Centricon (Millipore), after which protein concentration was measured with the Bradford method (Bio-Rad). Polyclonal antibodies against His-tagged vMAP (1-135) were produced in two rabbits.
Plasmids. Unless specified, all constructs were derived from pcDNA5/FRT/TO (Invitrogen) or pEF-IRES-puro [44] . A DNA fragment corresponding to the cHV-68 vMAP coding sequence was amplified from S11 genomic DNA by PCR and cloned into pcDNA5/ FRT/TO between BamHI and XhoI. To generate GFP fusion proteins, vMAP or vMAP (1-49) and its derivatives were PCR amplified and ligated to pEGFPN1 digested with BglII and SalI. Mutations in the vMAP gene were generated by PCR using oligonucleotide-directed mutagenesis. All constructs were sequenced with an ABI PRISM 377 automatic DNA Sequenzer. Constructs expressing the HA-tagged and GFP-tagged Bcl-2 family proteins were kindly provided by J. Marie Hardwick (John Hopkins University), Beth Levine (UT-Southwestern Medical Center), and Richard J. Youle (National Institutes of Health), respectively. HA-Bcl-x L and Flag-Bax were amplified by two-step PCR using GFP-Bcl-x L and GFP-Bax as templates and cloned into pcDNA5/ FRT/TO between the BamHI and XhoI sites. Bcl-2 was cloned into pEYFP-C1 at the BamHI site, and Bax and Bid were cloned into pECFP-C1 between the BamHI/XhoI sites, respectively. To produce His-tagged vMAP protein from E. coli, vMAP (1-135) was PCR amplified and cloned into pQE40 (Qiagen). To express GST fusion proteins in mammalian cells, vMAP sequences were PCR amplified and cloned into pDEF3 digested with KpnI and EcoRV.
Immunoblotting and immunoprecipitation. For immunoblotting, polypeptides were resolved by SDS-PAGE and transferred to PVDF membranes (Bio-Rad). Immunoblot detection was performed with anti-V5 (1:5000; Invitrogen), M2 anti-Flag (1:5000; Sigma), anti-GST (1:2000; Santa Cruz Biotechnology), anti-VDAC (porin 31HL) (1:1000; CALBIOCHEM), anti-Bax (6A7, 1:1000, Pharmingen), anti-COX4 (1:100; Clontech), anti-Bcl-2 (1:100, Santa Cruz Biotechnology), antiBcl-x L (1:100, Pharmingen), or anti-cytochrome c (1:200, Clontech; 1:1000, Pharmingen). Rabbit anti-vMAP serum was diluted 1:3000 for immunoblots. Proteins were visualized using a chemiluminescence detection reagent (Pierce) and quantified using a Fuji Phosphor Imager.
For immunoprecipitation, cells were harvested and then lysed with 1% CHAPS buffer (Cell Signaling) supplemented with 1 mM dithiothreitol (DTT) and protease inhibitor cocktail (Roche). After pre-clearing with protein A/G-agarose beads for 1 h at 4 8C, wholecell lysates were used for immunoprecipitation. Generally, 1-4 lg of commercial antibody or 1 ll of vMAP antiserum was added to 1 ml cell lysate, which was incubated at 4 8C for 8 to 12 h. After addition of protein A/G-agarose beads, the incubation was further extended for 1 h. The beads were extensively washed with lysis buffer, and the immunoprotein precipitates were eluted with SDS loading buffer by boiling for 5 min.
Immunofluorescence microscopy. Sixteen hours after transfection or electroporation, cells were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.2% (v/v) triton X-100 for 15 min, blocked with 10% goat serum in PBS for 30 min, and reacted with diluted primary antibody in PBS for up to 2 h at room temperature. After incubation, cells were washed extensively with PBS, incubated with the appropriate secondary antibody diluted in PBS for 30 min at room temperature, and washed three times with PBS. Mitochondrial staining was performed with 250 nM MitoTracker (Molecular Probes) for 20 min followed by washing with PBS at room temperature for 5 min. Alternatively, mitochondria were visualized using antibodies against mitochondrial proteins including cytochrome c and HSP60. Confocal microscopy was performed using a Leica TCS SP laserscanning microscope (Leica Microsystems) fitted with a 1003 Leica objective (PL APO, 1.4NA) and Leica imaging software. Images were collected at 512 3 512-pixel resolution. The stained cells were optically sectioned in the z-axis, and the images in the different channels (photo multiplier tubes) were collected simultaneously. The step size in the z-axis varied from 0.2 to 0.5 lm to obtain 16 slices per imaged file. The images were transferred to a Macintosh G4 computer (Apple Computer) and Photoshop (Adobe) was used to render the images.
For immunofluorescence microscopy, antibodies were directed against cytochrome c (1:200), Bax 6A7 (1:100; Pharmingen), HSP60 (1:100; Santa Cruz Biotechnology), vMAP (1:100), V5 (1:100; Invitrogen), or VDAC 31HL (1:100; CALBIOCHEM). All conjugated secondary antibodies were obtained from Molecular Probes and diluted at 1:1000 or 1:500. These included Alexa 488-conjugated goat anti-rabbit IgG, Alexa 568-conjugated goat anti-mouse IgG, Alexa 488-conjugated goat anti-mouse IgG, Alexa 594-conjugated donkey anti-goat IgG, Alexa 488-conjugated donkey anti-rabbit IgG, and Alexa 594-conjugated donkey anti-mouse IgG.
GST pull-down. In vitro GST pull-down was similar as previously described [45] . Briefly, E. coli (BL21) cells were induced with IPTG (1 lM) for 2 h and lysed with PBS containing 0.1% sarcosyl. GST or GST fusions were purified with glutathione-conjugated Sepharose beads and either used for immediate experiments or stored at À20 8C for future experiments. Then, whole-cell lysates were mixed with loaded glutathione-conjugated Sepharose and binding was extended at 4 8C for up to 2 h. After extensive washing, protein precipitates were resolved by SDS-PAGE and transferred to PVDF membrane, followed by immunoblotting. For mammalian GST pull-down, 293T cells expressing GST fusion proteins and Bcl-2 family proteins were harvested and lysed with 1% CHAPS buffer (50 mM HEPES [pH 7.4]; 100 mM NaCl; 10 mM Tris; 1 mM EDTA; 1% CHAPS) supplemented with protease inhibitor cocktail (Roche). Supernatants after centrifugation procedures were pre-cleared with 15 ll of protein A/G beads at 4 8C for 1 h, after which 40 ll of 50% glutathione-conjugated Sepharose beads was added and binding was extended for 2 to 3 h at 4 8C. Protein precipitates were washed extensively with lysis buffer and analyzed by immunoblotting.
Yeast two-hybrid screen. The yeast two-hybrid screen was performed as previously described [45, 46] . Yeast strain AH109 bearing the Gal4-vMAP (50-157) fusion gene plasmid was used to screen a cDNA library generated from EBV-immortalized B cells.
Mitochondrial enrichment. To obtain the mitochondrion-enriched HM fraction, 293T or NIH3T3 cells were harvested and washed with ice-cold PBS and resuspended with hypotonic buffer (10 mM Tris; 250 lM sucrose; 20 mM HEPES [pH 7.4]; 0.2 mM EDTA) supplemented with 1 mM DTT and protease inhibitor cocktail. The suspension was incubated on ice for 15 min and lysed with Nitrogen Bomber (Parr Instrument Company) at 250 psi for 15 min. Nuclei and unbroken cells were removed by centrifugation at 700g for 10 min. The supernatant at this point was regarded as whole cell lysate and was subjected to centrifugation at 6,000g for 15 min. The pellet was then resuspended with hypotonic buffer and centrifuged at 6,000g for 15 min; this process was repeated twice to obtain the mitochondrionenriched fraction. The supernatant was further centrifuged at 100,000g for 90 min to yield the cytosolic fraction (supernatant), and the pellet was collected and regarded as the light membrane fraction. When cytochrome c release was examined, the step to obtain light membranes was skipped.
Apoptosis assay. Stably transfected NIH3T3 cells were grown in complete DMEM with 2 lg/ml puromycin. Cells, 1 3 10 6 per well, were used for apoptosis induction with 1 lM ST for up to 16 h. After treatment, cells were harvested with cell dissociation buffer (Sigma) and fixed with 70% ethanol overnight. After staining the cells with PI for 30 min at room temperature, DNA content was measured with flow cytometry and analyzed with CellQuest (BD Biosciences). Alternatively, cells were treated with other apoptogenic agents (TNF-a plus cycloheximide, VESICULAR STOMATITIS infection, nocodazole), and sub-G1 cells were measured as described above.
For cytochrome c release, NIH3T3 cells were induced with 1 lM of ST for 4 h and harvested. The mitochondrion-enriched fraction was obtained as described above. Cytochrome c and mitochondrial membrane marker COX4 were detected by immunoblotting using the antibody from the ApoAlert kit (Clontech). For Bax mitochondrial translocation, cells were stimulated with 1 lM ST for 4 h and processed for intracellular fractionation as described above. For Bax activation, cells were stimulated with 1 lM ST for 4 h, and whole-cell lysates in 1% CHAPS buffer were precipitated with the mouse 6A7 monoclonal antibody or the rabbit P-19 polyclonal antibody, and protein precipitates were analyzed by immunoblotting.
For cHV-68DK3-GFP infection in wt and Bax
Bak À/À DKO MEF cells, the activated caspase 3 was measured by intracellular staining according to manufacturer's instruction (BD Pharmingen), followed by flow cytometry analysis. Meanwhile, dead cells were stained with trypan blue and counted under light microscope.
In vitro mitochondrion recruitment of Bcl-2. Bcl-2 was in vitro translated from TNT-coupled reticulocyte lysate systems (Promega) and labeled with [
35 S]-methionine/cysteine. The mitochondrionenriched HM fraction was obtained as described above from NIH3T3/puro or NIH3T3/vMAP cells. Protein was measured with the Bradford method and 50 lg of mitochondrial proteins were mixed with 100 ll of reticulocyte lysates containing the radioactively labeled Bcl-2. The mixtures were incubated at 30 8C for 2 h and mitochondria were pelleted at 13,000 rpm for 15 min. While the supernatants were collected as membrane-free Bcl-2, the pellets were washed twice with hypotonic buffer and resuspended in PBS as mitochondrion-associated Bcl-2. Proteins were then analyzed by gradient (4%-12%) SDS-PAGE and Phosphor Image reader.
Fluoresence resonance energy transfer (FRET) assay. NIH3T3/vec, NIH3T3/vMAP, and NIH3T3/vMAPD20 were transfected with pEYFPBcl-2 and pECFP-Bid. At 36 h post-transfection, cells were harvested with dissociation buffer and washed twice with room temperature PBS containing 0.5% bovine serum albumin. Next, cells were subjected to flow cytometry that is equipped with fluorochrome excitation capability. Figure S1 . The Mitochondrion-Dependent Apoptosis Limits cHV-68 Replication (A) cHV-68 replication in wild-type (wt) or Bax 
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